MelindaLTelliMD

Oncology • Stanford, CA

Breast Cancer

Associate Professor of Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Telli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Telli's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-723-0074

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2002 - 2005
George Washington University School of Medicine and Health SciencesClass of 2002

Certifications & Licensure

CA State Medical License 2003 - 2025
FL State Medical License 2020 - 2022

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women Start of enrollment: 2000 Oct 01
Completed
Phase 2
Development of Vitamin D as a Therapy for Breast Cancer - Phase 2 Start of enrollment: 2008 Apr 01
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Vitamin D and Breast Cancer: Does Weight Make a Difference? Start of enrollment: 2011 Nov 01
Terminated
Phase 2
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Start of enrollment: 2012 Jun 13
Completed
Phase 2
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

4 citations
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen
Breast Cancer. 2024-09-01
18 citations
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft
Journal of the National Comprehensive Cancer Network. 2024-07-01
Tumor-infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California Breast Cancer Family Registry.
Julia D Ransohoff, Iain Miller, Jocelyn Koo, Vishal Joshi, Allison W Kurian
JNCI Cancer Spectrum. 2024-02-29

Lectures

Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in ear...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

NCCN: Updated Guidelines Reflect Advances, ‘Immunotherapy Era’ for Breast CancerApril 15th, 2019
Technique Could Help Identify Patients Who Would Suffer Chemo-Induced Heart DamageApril 18th, 2016
Anthracycline-Free Neoadjuvant Regimen Safe, Effective for TNBCMarch 6th, 2021
Join now to see all

Professional Memberships